Minerva Neurosciences Q1 2023 Earnings Report $2.16 +0.02 (+0.93%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Minerva Neurosciences EPS ResultsActual EPS-$1.31Consensus EPS -$1.63Beat/MissBeat by +$0.32One Year Ago EPSN/AMinerva Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMinerva Neurosciences Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesNERV Earnings History Genesis leading the smart algo revolution? (Ad)I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Minerva Neurosciences Earnings HeadlinesStockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)December 20 at 2:11 AM | americanbankingnews.comStockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)December 15, 2024 | americanbankingnews.comCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.December 21, 2024 | ProsperityPub (Ad)Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 6, 2024 | markets.businessinsider.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 5, 2024 | globenewswire.com'It has meant everything': Minerva girls win second straight cross country state titleNovember 4, 2024 | msn.comSee More Minerva Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email. Email Address About Minerva NeurosciencesMinerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.View Minerva Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
